Antibody Ingredients TRIZ Cases

Modifying antibody Fc regions reduces off-target binding while blocking CD47-SIRPα interactions to restore macrophage phagocytosis of cancer cells.

Tesirine-conjugated antibodies target EGFRvIII variants, reducing off-target toxicity while enhancing therapeutic efficacy against specific cancers.

Human antibodies targeting extended Type I chain glycosphingolipids mediate cellular and complement-dependent cytotoxicity against malignant cells.

Targeted mutations in light and heavy chain variable regions improve antibody stability while maintaining tumor inhibition efficacy.

Engineered PD-1 binding domains achieve higher affinity and potency to activate immune responses against cancer while reducing toxicity.

Fc region-mediated FcγRIIB recruitment overcomes weak inhibition efficacy in prior art antibodies.

Combining HDAC inhibitors with PD-1 antibodies enhances anti-tumor immune responses.

Combining anti-CSF-1R antibodies to deplete immunosuppressive M2 macrophages with anti-PD-L1 therapy restores T-cell function after prior treatment failure.

Flow microreactor micromixing overcomes slow thermodynamic batch reactions to produce high-purity antibody derivatives.

Specific amino acid mutations stabilize VH domains, enabling bacterial expression and intracellular targeting.

Anti-CD47 antibody variable regions target tumor cells to inhibit growth while avoiding hemagglutination.

A bispecific antibody construct binds human CD70 on target cells and CD3 on T cells to bridge immune recognition.

Novel TIGIT antibodies overcome immune checkpoint inhibition by blocking CD155 interaction to restore T cell activity.

A pharmaceutical composition combining an immunosuppressant with a transglutaminase 2 inhibitor to treat atopic dermatitis.

Antibodies targeting truncated O-glycans on MUC16 inhibit PI3K/Akt signaling, addressing the low response rate of conventional pancreatic cancer therapies.

Local antibody expression via oncolytic virus overcomes cold tumor resistance by boosting T cell infiltration and efficacy.

Novel antibodies target integrin alpha 11 beta 1 to block collagen interaction and inhibit myofibroblast differentiation.

Multivalent polypeptides bind CD3 and CD11b markers to target suppressive T cells, resolving immune evasion in cancer and HIV treatment.

Co-administering sheddase inhibitors prevents soluble CD30 generation, thereby reducing organ toxicity while maintaining therapeutic efficacy.

Merges cytotoxic acryloyl distamycin derivatives with monoclonal antibodies to resolve limited monotherapy efficacy through synergistic tumor regression.

Combining anti-STAT3-TLR9 conjugates with checkpoint inhibitors overcomes the immunosuppressive tumor microenvironment.

B7-H4 antibodies target high B7-H4 expression to reduce activity, revitalizing treatment response in cancers resistant to PD-1 therapies.

Cancer microenvironment-targeting anti-podocalyxin antibody recognizes specific glycopeptides on abnormal blood vessels.

Anti-CD44 therapy disrupts bone marrow protection, allowing T cell redirection to effectively kill leukemia stem cells.

Anti-C10orf54 antibodies block immune suppression by binding the antigen, enabling T cell activation and direct tumor cell killing.

Phenotypic markers distinguish B10 cells from pathogenic subsets, resolving non-specific depletion trade-offs in autoimmune therapy.

Anti-CD228 antibodies replace surgical lymph node removal to reduce cancer burden without physical trauma or systemic toxicity.

Anti-PD-1 antibodies reverse iNKT cell anergy induced by repeated ligand stimulation, restoring potent anti-tumor activity.

Radiolabeled VHH nanobodies replace invasive biopsies to quantify LAG-3 expression, resolving heterogeneity issues that limit patient selection.

Antibodies bind TIGIT to block inhibitory ligand interactions, resolving immune suppression that hampers cancer treatment effectiveness.

Recombinant antibodies with modified binding specificity inhibit PD-1 ligand interactions, resolving insufficient clinical response in cancer therapy.

Spesolimab targets the IL-36R pathway to resolve incomplete symptom relief from traditional treatments.

Combining amplified alloreactive NK cells from pooled umbilical cord blood with therapeutic antibodies increases cytotoxic activity.

GPR84 antagonists block immunosuppressive myeloid-derived suppressor cells to enhance T-cell cytotoxicity and improve cancer treatment efficacy.

Antibody-drug conjugates bind Globo series antigens to deliver cytotoxic payloads, reducing toxicity to normal cells.

Variant antibody drug conjugates utilize Fc region cysteine substitution to modulate receptor affinity.

Biomarkers predict efficacy and immune-related adverse events for CTLA-4 and PD-1 blockade therapies, enabling personalized melanoma treatment.

Engineering the Fc region of a PD-L1 binding antibody enhances activating Fcγ receptor affinity while blocking inhibitory FcγRIIB signaling.

Combining PD-1 axis binding antagonists with anti-GPC3 antibodies targets tumor cells directly.

A recombinant antibody binds canine IgE to reduce free serum levels.

Asymmetric bispecific antibody reduces non-specific cytokine release while maintaining strong anti-tumor activity against small cell lung cancer.

A humanized anti-IgE antibody crosslinks CD23 receptors on B lymphocytes to inhibit antigen-specific IgE production.

Optimized variable domains improve clinical response across cancer types by resolving efficacy versus specificity trade-offs.

Carrier protein conjugation enhances immunogenicity of poorly immunogenic linker peptides to generate specific monoclonal antibodies.

Antibodies targeting GPR49 reduce cancer stem cell abundance by 20% to 50%, addressing inadequate treatment effectiveness in colon cancer.

Fc glycoengineering attaches homogeneous N-glycans to anti-CD20 antibodies, resolving immunogenicity from heterogeneous production while boosting ADCC.

PD-1 inhibitors reduce cancer pain and tumor burden by activating the immune system, decreasing reliance on opioid analgesics.